Get the Stockscreener App
1.07
7.76%
-0.09
Inovio Pharmaceuticals Inc stock is traded at $1.07, with a volume of 3.30M.
It is down -7.76% in the last 24 hours and down -6.14% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.16
Open:
$1.17
24h Volume:
3.30M
Relative Volume:
1.28
Market Cap:
$88.03M
Revenue:
$65,300
Net Income/Loss:
$-84.93M
P/E Ratio:
-0.6265
EPS:
-1.708
Net Cash Flow:
$-83.57M
1W Performance:
-18.32%
1M Performance:
-6.14%
6M Performance:
-48.31%
1Y Performance:
-49.53%
1-Day Range:
$1.06
$1.17
1-Week Range:
$1.06
$1.30
52-Week Range:
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.07 | 95.44M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio gains on late-stage trial win for DNA shot - MSN
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co. - Moomoo
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision - Bez Kabli
INO stock edges up after hours as partner reports success in cervical dysplasia trial - MSN
INO Maintained by HC Wainwright & Co. -- Price Target Lowered to $2.50 - GuruFocus
H.C. Wainwright lowers Inovio stock price target on share count - Investing.com UK
H.C. Wainwright lowers Inovio stock price target on share count By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $2.5 - Moomoo
INOVIO Partner Reports Phase 3 Success for HPV Therapy in China - MyChesCo
Inovio Pharmaceuticals shareholders back board as INO-3107 FDA review advances - MSN
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Q4 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Participate in Upcoming Scientific and Investor Conferences - marketscreener.com
Rare disease DNA medicine on agenda as INOVIO hits June conferences - Stock Titan
Inovio Pharmaceuticals (INO) Holds Near Support Amid Slight DeclineReversal Setup Alerts - thelegaladvocate.com
Inovio Brass Hit With Suit Over FDA Approval Claims - Law360
Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date - Kavout
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances - Yahoo Finance
Inovio Pharmaceuticals (INO) Stock Rises on Positive Trial Resul - GuruFocus
Inovio Pharmaceuticals (INO) Shares Rise on Positive Trial Resul - GuruFocus
Inovio gains on late-stage trial win for DNA shot (INO:NASDAQ) - Seeking Alpha
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China - Sahm
Positive Phase 3 Results for Inovio (INO) Partnered VGX-3100 in China - GuruFocus
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits
ApolloBio reports positive phase 3 results for VGX-3100 in China - Investing.com UK
Inovio Shareholders Endorse Governance Changes and Leadership - The Globe and Mail
Inovio (NASDAQ: INO) director awarded RSUs and 41,800 options - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Inovio (NASDAQ: INO) grants RSUs and stock options to director Ann Calby Miller - Stock Titan
Equity grants to Inovio (NASDAQ: INO) director David Weiner disclosed - Stock Titan
Inovio (NASDAQ: INO) director receives RSUs and stock options grant - Stock Titan
Inovio (NASDAQ: INO) director granted 34,200 RSUs and 41,800 options - Stock Titan
INOVIO (INO) Chief Scientific Officer reports RSU vesting, tax withholding and new stock option awards - Stock Titan
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):